ArticleEuropean journal of nuclear medicine and molecular imaging2022
Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy.
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiomics as a tool for predicting biochemical recurrence after total prostatectomy: a systematic review and meta-analysis.International urology and nephrology · 2026Pooled it
- Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [European urology · 2024Trial
- Response to: 'Methodological concerns on prostate-specific membrane antigen (PSMA) immunohistochemistry for predicting PSMA-PET avidity'.BJU international · 2026Article
- Baseline Ga-68 PSMA PET/CT-derived volumetric parameters as predictors of biochemical recurrence following radical prostatectomy.Annals of nuclear medicine · 2026Article
- Limited incremental prognostic value of pretreatment MRI andAbdominal radiology (New York) · 2026Article
- Correlation of intraprostatic lesional SUVmax during PSMA PET/CT and adverse pathology at radical prostatectomy.Prostate cancer and prostatic diseases · 2026Article
- Development and multicohort external validation of a preoperative [18F]PSMA-1007 PET-derived deep learning score and multimodal model for predicting biochemical recurrence-free survival after radical prostatectomy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI-Driven Biomarkers.Cancers · 2025Review
- Primary Score as a Predictive Marker in Intermediate-Risk Prostate Cancer: Insights from PSMA PET/CT Imaging.Nuclear medicine and molecular imaging · 2025Article
- PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Baseline PSMA PET/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients.European radiology · 2025Article
- Review
- Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics.BJU international · 2024Article
- Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [European journal of nuclear medicine and molecular imaging · 2024Article
- PSMA PET/CT in the low- to intermediate-risk prostate cancer: when and why?Asian journal of andrology · 2024Article
- Update on PSMA-based Prostate Cancer Imaging.Seminars in nuclear medicine · 2024Review
- Quantitative PSMA-PET parameters in localized prostate cancer: prognostic and potential predictive value.Radiation oncology (London, England) · 2024Article
- Development and validation of [18 F]-PSMA-1007 PET-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy.European journal of nuclear medicine and molecular imaging · 2024Article
- Direct Patlak Reconstruction of [International journal of molecular sciences · 2023Article
- Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer.Radiation oncology (London, England) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe prognostic value of PSMA intensity on PSMA PET/CT due to underlying biology and subsequent clinical implications is an emerging topic of interest. We sought to investigate whether primary tumour PSMA PET intensity contributes to pre- and post-operative prediction of oncological outcomes following radical prostatectomy.
methodsWe performed a retrospective cohort study of 848 men who underwent all of multiparametric MRI (mpMRI), transperineal prostate biopsy, and
resultsAfter a median follow-up of 41 months, 219 events occurred; the estimated 3-year BRFS was 79% and the 5-year BRFS was 70%. Increasing PSMA intensity was associated with less favourable BRFS overall (Log rank p < 0.001), and within subgroups of Gleason score category (Log rank p < 0.03). PSMA intensity was significantly associated with shorter time to biochemical recurrence, after adjusting for pre-operative (HR per 5-unit SUVmax increase = 1.15) and post-operative (HR per 5-unit SUVmax increase = 1.10) parameters.
conclusionThese results in a large series of patients confirm PSMA intensity to be a novel, independent prognostic factor for BRFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.